title: Interleukin and interleukin receptor gene polymorphisms and susceptibility to melanoma.
abstract: Genetic variation in immune-regulating components such as cytokines may lead to interindividual differences in immunosuppression response and susceptibility to melanoma. We evaluated the associations between genetic variants in five interleukins (IL) and IL receptor genes (IL-4, IL-4R, IL-6, IL-6R, and IL-10) and the risk of melanoma. Twenty-five single nucleotide polymorphisms (SNPs) were selected that are functionally relevant or tagging SNPs of each gene. We conducted a nested case-control study of 219 female patients and 219 matched controls within the Nurses' Health Study. We observed that in the IL-6R gene, four SNPs in linkage disequilibrium were associated with an increased risk of melanoma. Three are located in introns (rs6684439, rs4845618, and rs4845622), and one is a nonsynonymous SNP in exon 9 [rs8192284 (Asp358Ala)]. An elevated risk of melanoma was observed in the heterozygous groups of these SNPs with odds ratio of 1.74 [(95% confidence interval, 1.07, 2.81) for rs6684439, 1.72 (1.04, 2.84) for rs4845618, 1.69 (1.03, 2.75) for rs4845622, and 1.68 (1.04, 2.73) for rs8192284]. But these associations were not observed in the homozygous variant group with odds ratios ranging from 0.93 to 1.03. We did not find significant results for the SNPs in the other four genes. These data suggest the involvement of IL-6R in melanoma development. Further studies are needed to confirm these findings.
authors.affiliation: Department of aEpidemiology, Program in Molecular and Genetic Epidemiology, Harvard School of Public Health, Boston, Massachusetts 02115, USA. fgu@hsph.harvard.edu
authors.forename: Fangyi
authors.initials: F
authors.lastname: Gu
authors.forename: Abrar A
authors.initials: AA
authors.lastname: Qureshi
authors.forename: Tianhua
authors.initials: T
authors.lastname: Niu
authors.forename: Peter
authors.initials: P
authors.lastname: Kraft
authors.forename: Qun
authors.initials: Q
authors.lastname: Guo
authors.forename: David J
authors.initials: DJ
authors.lastname: Hunter
authors.forename: Jiali
authors.initials: J
authors.lastname: Han
mesh_terms: D000328:Adult; D000483:Alleles; D016022:Case-Control Studies; D005091:Exons / Q000235:genetics; D005260:Female; D020022:Genetic Predisposition to Disease; D006801:Humans; D007378:Interleukins / Q000235:genetics*; D007438:Introns; D008545:Melanoma / Q000235:genetics*; D008875:Middle Aged; D020641:Polymorphism, Single Nucleotide; D011401:Promoter Regions, Genetic; D018123:Receptors, Interleukin / Q000235:genetics*; D019947:Receptors, Interleukin-6 / Q000235:genetics*; D012878:Skin Neoplasms / Q000235:genetics*
chemical_list: D007378:Interleukins; D018123:Receptors, Interleukin; D019947:Receptors, Interleukin-6
references.citation: Eur J Immunogenet. 2003 Dec;30(6):409-14
references.pmid: 14675394
references.citation: Hum Mol Genet. 2001 Mar 15;10(6):591-7
references.pmid: 11230178
references.citation: Melanoma Res. 2005 Jun;15(3):199-204
references.pmid: 15917702
references.citation: Nucleic Acids Res. 2003 Jul 1;31(13):3812-4
references.pmid: 12824425
references.citation: Genes Immun. 2004 Sep;5(6):513-6
references.pmid: 15306846
references.citation: Int J Cancer. 1997 May 16;71(4):630-7
references.pmid: 9178819
references.citation: J Immunol. 1993 Jan 15;150(2):353-60
references.pmid: 8419468
references.citation: Melanoma Res. 2005 Feb;15(1):53-60
references.pmid: 15714121
references.citation: Cancer Epidemiol Biomarkers Prev. 2005 Jun;14(6):1539-44
references.pmid: 15941969
references.citation: Immunol Today. 1984 Oct;5(10):291-3
references.pmid: 25290545
references.citation: Cancer Genet Cytogenet. 2007 Jul 1;176(1):54-7
references.pmid: 17574964
references.citation: Nat Genet. 2005 Nov;37(11):1217-23
references.pmid: 16244653
references.citation: BMC Bioinformatics. 2006 Mar 22;7:166
references.pmid: 16551372
references.citation: J Interferon Cytokine Res. 1999 Jul;19(7):697-703
references.pmid: 10454339
references.citation: Int J Cancer. 1994 Mar 1;56(5):755-60
references.pmid: 8314354
references.citation: J Clin Invest. 1998 Oct 1;102(7):1369-76
references.pmid: 9769329
references.citation: BMC Bioinformatics. 2005 Mar 18;6:60
references.pmid: 15774022
references.citation: Proc Natl Acad Sci U S A. 1992 Nov 15;89(22):10915-9
references.pmid: 1438297
references.citation: Cancer Immunol Immunother. 2007 Mar;56(3):371-9
references.pmid: 16835788
references.citation: Proc Natl Acad Sci U S A. 1992 Oct 1;89(19):9215-9
references.pmid: 1409627
references.citation: Int J Epidemiol. 2006 Dec;35(6):1514-21
references.pmid: 16943234
references.citation: Hum Mol Genet. 2006 Jun 1;15(11):1914-20
references.pmid: 16644865
references.citation: Eur J Cancer. 2007 Mar;43(4):762-8
references.pmid: 17258448
references.citation: Melanoma Res. 2002 Oct;12(5):465-9
references.pmid: 12394188
references.citation: J Infect Dis. 2006 Apr 15;193(8):1054-62
references.pmid: 16544245
references.citation: J Nutr. 2007 Jan;137(1 Suppl):194S-199S
references.pmid: 17182825
references.citation: Genes Immun. 2001 Feb;2(1):25-31
references.pmid: 11294564
references.citation: J Comput Biol. 1997 Fall;4(3):311-23
references.pmid: 9278062
references.citation: J Immunol. 1998 Apr 15;160(8):3783-9
references.pmid: 9558081
references.citation: J Immunol. 1994 May 15;152(10):4958-68
references.pmid: 8176214
references.citation: In Silico Biol. 2003;3(3):235-40
references.pmid: 12954087